Abivax To Launch ‘Triple-Action’ COVID-19 Therapy Trial
Data Show Anti-inflammatory ABX464 inhibits SARS-CoV-2 Viral Replication In Lung
Abivax will test its anti-inflammatory ABX464 in early COVID-19 patients after the small molecule showed it could reduce SARS-CoV-2 viral replication in human lung tissue in addition to its anti-inflammatory and tissue-healing effects.
You may also be interested in...
The French biotech's CEO tells Scrip the firm now has the time and resources to sign up a big pharma partner for its ulcerative colitis, RA and Crohn’s candidate.
Shrinking cash and COVID-19 uncertainty have prompted Nordic Nanovector to slash costs and focus purely on its lead asset’s pivotal trial in third-line follicular lymphoma.
Sanofi to sell most of its Regeneron stake, with much of it being re-purchased by Regeneron, but both stressed the move would not hurt their long established and very profitable drug-development collaboration.